Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

Key Takeaway: Invivyd, Inc. will hold a conference call on August 10, 2023, to review its financial results for Q2 2023 and discuss recent business highlights. The call aims to inform stakeholders about the company's developments in antibody-based therapies targeting viral diseases, including COVID-19. Interested participants can register for the webcast and a replay will be available shortly following the call.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is hosting a conference call to discuss positive financial results.
  • The company is making progress in developing antibody-based therapies.
  • Invivyd's technology aims to protect vulnerable populations from serious viral diseases.

Full Press Release Details

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available in the investor section of the company’s website approximately two hours after the end of the call. Those who plan on participating are advised to join 15 minutes prior to the start time.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Kate Burdick, Evoke Canale
Chris Brinzey, ICR Westwicke

Frequently Asked Questions

When will Invivyd host its next conference call?

Invivyd will host its next conference call on August 10, 2023, at 4:30 p.m. ET.

What will Invivyd discuss during the conference call?

The call will cover financial results for Q2 2023 and recent business highlights.

How can I participate in the Invivyd conference call?

Listeners can register for the webcast via the provided link; analysts can join the Q&A via another link.

Is a replay of the conference call available?

Yes, a replay will be available in the investor section of Invivyd's website about two hours later.

What is Invivyd's main focus?

Invivyd focuses on delivering antibody-based therapies to protect against viral infectious diseases.

Last updated: Aug 3, 2023